Cover Image
市場調查報告書

狂犬病(恐水症):開發中產品分析

Rabies - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 219865
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
狂犬病(恐水症):開發中產品分析 Rabies - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 72 Pages
簡介

狂犬病(恐水症)是由感染的動物其唾液傳染之致死性病毒,一般經咬傷傳染。其症狀有身體部分感覺消失、肌肉功能消失、吞嚥障礙、興奮、發燒、痙攣等。致病因子有與野生生物接觸、與未接種疫苗之寵物接觸等。

本報告涵括全球狂犬病(恐水症)治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

狂犬病(恐水症) - 概要

狂犬病(恐水症) - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

狂犬病(恐水症) - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

狂犬病(恐水症)的治療藥開發企業

  • Beijing Minhai Biotechnology Co Ltd
  • Celltrion Inc
  • Curevac AG
  • Humabs BioMed SA
  • Indian Immunologicals Ltd
  • Kamada Ltd
  • Molecular Targeting Technologies Inc
  • NanoViricides Inc
  • Novavax Inc
  • PaxVax Inc
  • Sanofi Pasteur SA
  • Synermore Biologics Co Ltd
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Zydus Cadila Healthcare Ltd

藥物簡介

狂犬病(恐水症) - 暫停中的計劃

狂犬病(恐水症) - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9260IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2017, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rabies - Overview
    • Rabies - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rabies - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rabies - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Celltrion Inc
    • Curevac AG
    • Humabs BioMed SA
    • Indian Immunologicals Ltd
    • Kamada Ltd
    • Molecular Targeting Technologies Inc
    • NanoViricides Inc
    • Novavax Inc
    • PaxVax Inc
    • Sanofi Pasteur SA
    • Synermore Biologics Co Ltd
    • Trellis Bioscience Inc
    • VBI Vaccines Inc
    • Zydus Cadila Healthcare Ltd
  • Rabies - Drug Profiles
    • (Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNSP-333S1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTP-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-8102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMT-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadorameran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RabiCide-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rabimabs - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RabiVir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVC-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVC-58 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SO-57 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOJB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YSON-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rabies - Dormant Projects
  • Rabies - Product Development Milestones
    • Featured News & Press Releases
      • Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference
      • Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine
      • Nov 07, 2016: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
      • Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
      • Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
      • Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment
      • Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies
      • Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
      • Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability
      • Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel
      • Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America
      • May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product
      • Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rabies, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Rabies - Pipeline by Celltrion Inc, H1 2017
  • Rabies - Pipeline by Curevac AG, H1 2017
  • Rabies - Pipeline by Humabs BioMed SA, H1 2017
  • Rabies - Pipeline by Indian Immunologicals Ltd, H1 2017
  • Rabies - Pipeline by Kamada Ltd, H1 2017
  • Rabies - Pipeline by Molecular Targeting Technologies Inc, H1 2017
  • Rabies - Pipeline by NanoViricides Inc, H1 2017
  • Rabies - Pipeline by Novavax Inc, H1 2017
  • Rabies - Pipeline by PaxVax Inc, H1 2017
  • Rabies - Pipeline by Sanofi Pasteur SA, H1 2017
  • Rabies - Pipeline by Synermore Biologics Co Ltd, H1 2017
  • Rabies - Pipeline by Trellis Bioscience Inc, H1 2017
  • Rabies - Pipeline by VBI Vaccines Inc, H1 2017
  • Rabies - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Rabies - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Rabies, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top